Share Based Awards |
9 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Jan. 31, 2020 | ||||||||||
Share-based Payment Arrangement [Abstract] | ||||||||||
Share Based Awards |
Note 11 – Share Based Awards
Effective August 2019, shareholders approved the 2019 Equity Incentive Plan (the “Plan”) which allows us to incentivize key employees, consultants, and directors with long term compensation awards such as stock options, restricted stock, and restricted stock units (collectively, the “Awards”). The number of shares issuable in connection with Awards under the Plan may not exceed 8,750,000.
In October 2019, we issued options to purchase 350,000 shares of common stock valued at $477,500. Options to purchase 200,000 shares vest ratably over a 2 year period and expire in October 2029. Options to purchase 150,000 shares vest ratably over a 3 year period and expire in October 2024. All of the options were issued at an exercise price of $2.10 which equaled the stock price on the date of issuance. We used the Black-Scholes Model to estimate the fair value of the stock options issued using the following assumptions: (i) expected volatility – 75%, (ii) risk free interest rate – 1.59% or 1.74%, (iii) expected life – 5 or 10 years, and (iv) expected dividend yield of 0%.
In January 2020, we issued options to purchase 1,100,000 shares of common stock exercisable at $0.82 vesting quarterly over a 3 year period. These options were valued at $707,300. We also issued options to purchase 147,475 shares of common stock exercisable at $0.82. These options were valued at $94,826 and were vested in full upon issuance. All of these options were issued at an exercise price which equaled the stock price on the date of issuance. We used the Black-Scholes Model to estimate the fair value of the stock options issued using the following assumptions: (i) expected volatility – 75%, (ii) risk free interest rate – 1.74%, (iii) expected life – 10 years, and (iv) expected dividend yield of zero.
Compensation expense recognized in the three months ended January 31, 2020 was $149,462, of which $105,976 was included in general and administrative expenses and $43,486 was included in research and development expenses. Compensation expense recognized in the nine months ended January 31, 2020 was $161,529, of which $114,791 was included in general and administrative expenses and $46,738 was included in research and development expenses. There was no compensation expense recognized in the nine months ended January 31, 2019.
Options exercisable as of January 31, 2020 totaled $147,475. The remaining weighted average contractual term of the options outstanding at October 31, 2019 was 9.47 years. The aggregate intrinsic value of outstanding options, representing the excess of the stock price at January 31, 2020 of $1.74 over the exercise price of each option, was $1,147,677 at January 31, 2020. |